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INFECTION – Clinical Outcomes Studies
PIN1
COST AND QUALITY OF LIFE ISSUES ASSOCIATED WITH PROTEASE 
INHIBITOR-BASED COMBINATION THERAPY TO TREAT HEPATITIS C
Carter J1, Gao X1, Stephens JM1, Rustgi V2, Haider S3
1Pharmerit North America, LLC, Bethesda, MD, USA; 2Georgetown University Medical 
Center, Fairfax, VA, USA; 3Pﬁ zer Inc., New London, CT, USA
OBJECTIVES: To systematically analyze the literature to assess the economic and 
health-related quality of life (HRQoL) impact of adverse events (AEs) related to the 
addition of protease inhibitors (PI) to standard of care (SOC) for the treatment of 
hepatitis C (HCV). METHODS: A literature search (2000-Present) was conducted to 
identify and analyze clinical trials for PI triple therapy (PITT = PI + SOC) and SOC 
(PEGIFN/RBV for 48 weeks). HRQoL and safety data were synthesized by study 
design, sample characteristics, and AEs. Economic and resource use data were synthe-
sized in an economic analysis of AEs in PITT vs. SOC. Costs (2009) were derived 
from published literature. RESULTS: Twenty-three SOC and 7 PITT trials were identi-
ﬁ ed. Statistically signiﬁ cant (p = or <0.05) changes from baseline were most often seen 
in trials of SOC in the following domains: vitality, depression, physical limitations, 
and fatigue. The following 4 PITT-related AEs could be linked to HRQoL domains: 
anemia and depression were linked to fatigue and vitality, and headache and rash were 
linked to physical limitations. In terms of economic impacts, the costs to manage a 
PITT-related episode of anemia, depression, diarrhea, and rash were $4825, $2837, 
$566, and $633, respectively. The average AE cost in PITT ranged from $1732 to 
$3578. Corresponding costs in SOC ranged from $1608 to $2229. The treatment 
costs of PITT-related AEs were 30% (range 8–60%) higher than the cost of treating 
SOC-related AEs. CONCLUSIONS: The costs to manage PITT-related AEs appear 
higher than the costs of SOC-related AEs. Since PITT is associated with higher AE 
rates, it can also be expected to result in worse HRQoL. Gaps in symptom burden 
assessment with existing instruments also exist. Future studies should incorporate the 
economic burden of AEs and the appropriate use of HCV-validated instruments to 
capture potential HRQoL differences among treatment strategies.
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ESTIMATED IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ON LIFE EXPECTANCY, QUALITY-ADJUSTED LIFE-YEARS (QALYS) AND 
LIFETIME COSTS IN CHRONIC HEPATITIS C (CHC) PATIENTS
Cure S1, Bianic F1, Cawston H1, Dartois L1, Zhang H2
1i3 Innovus, Uxbridge, Middlesex, UK; 2Johnson & Johnson Pharmaceutical Services, LLC, 
Raritan, NJ, USA
OBJECTIVES: The World Health Organization considers hepatitis C a global burden. 
CHC is a curable disease since patients achieving SVR can remain virus-free. We 
evaluated CHC treatment for efﬁ cacy (SVR) and long-term effects on reduction of 
disease progression to advanced stages, improvement in quality of life, and reduction 
of health care costs. The objective was to estimate the burden of disease and impact 
of SVR in CHC patients on lifetime life-years (LY), QALYs and costs using a Markov 
model and published literature. METHODS: A systematic literature review identiﬁ ed 
publications reporting the cost-effectiveness of antiviral therapies in CHC (November 
2009). PubMed, CRD and Health Technology Assessment reports were searched. We 
selected all cost-effectiveness (CE) studies with a similar Markov structure including 
eight health states (SVR, mild/moderate CHC, compensated and decompensated cir-
rhosis, hepatocellular carcinoma [HCC], liver transplant and death). CE inputs were 
used to populate a Markov model to estimate average lifetime beneﬁ ts and costs 
associated with SVR and non-SVR. Age of entry in the model was 40 years. Costs 
were updated to 2008 Great Britain Pounds (GBP). Discount rates for costs and 
outcomes were 3.5%. RESULTS: 893 unique references were retrieved and 14 articles 
met the inclusion criteria. Compared to non-SVR patients, the SVR group was con-
sistently associated with more LYs (18.33, range [18.05;18.53] versus 17.49, range 
[16.17;18.51]) and more QALYs (15.81, range [14.8;17.87] versus 13.25, range 
[11.9;14.03]). Lifetime costs associated with non-SVR patients (£20,406, range 
[£7,186;£41,383]) were also consistently higher than with SVR patients (£11,156, 
range [£5,449;£14,582]). CONCLUSIONS: Using this model, the SVR group was 
consistently associated with longer life expectancy and more QALYs. Complications 
avoided by reaching SVR were associated with reduced lifetime CHC costs. It will be 
important to account for these correlations with lifetime beneﬁ ts and costs when the 
values of an antiviral treatment in CHC are evaluated.
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PRESCRIBER INFLUENCE ON THE PREVALENCE OF POTENTIAL 
ANTIRETROVIRAL DRUG-DRUG INTERACTIONS ON PRESCRIPTIONS 
IN SOUTH AFRICA
Katende-Kyenda NL1, Lubbe MS2, Serfontein JHP2, Truter I3
1Walter Sisulu University, Mthatha, Eastern Cape, South Africa; 2North-West University, 
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OBJECTIVES: The purpose was to determine the prevalence of potential drug-drug 
interactions (DDIs) between antiretroviral (ARV) drugs on prescriptions prescribed by 
general practitioners and specialists in South Africa and the evaluation of the pre-
scribed daily doses (PDDs) of the interacting drugs. METHODS: A quantitative, 
retrospective drug utilization study was performed on 49,995, 81,096 and 88988 ARV 
prescriptions claimed through a South African pharmacy beneﬁ t management 
company during 2005 to 2007. Potential DDIs between ARVs were identiﬁ ed and 
classiﬁ ed according to a clinical signiﬁ cance rating. The clinical signiﬁ cance ratings of 
potential DDIs are described in three degrees of severity, identiﬁ ed as major, moderate 
and minor as described by Tatro. (RSA Rand(R)/$US = 6.8595 on 31 December 2007). 
RESULTS: Antiretroviral drugs represented 0.91% of all drugs (N = 59 971 226) 
claimed during the three years at a total cost of N = R 5 758 783 544 (1.92%). The 
average cost of antiretroviral prescriptions decreased with 4.19% from 2005 (R524.40 
± R178.79) to 2007 (R502.41 ± R161.19). ARV prescriptions prescribed by general 
practitioners with potential DDIs and PDDs not according to recommended ARV 
dosing increased dramatically from 12.33% in 2005 to 24.26% in 2007. Those pre-
scribed by specialists increased from 15.46% in 2005 to 35.30% in 2006 and 
decreased to 33.16% in 2007. The highest percentage of ARV prescriptions with 
potential DDIs and PDDs not according to the recommended ARV dosing guidelines 
were identiﬁ ed in ARV regimens between lopinavir/ritonavir at PDD 1066.4 mg/264 mg 
and efavirenz at PDD 600 mg prescribed to patients 19 to 45 years. These regimens 
were mostly prescribed by general practitioners as compared to specialists. CONCLU-
SIONS: There is need for more education of prescribers to be aware of the potential 
medication-prescribing errors associated with highly active antiretroviral therapy 
which could lead to treatment failures, development of resistance and DDIs.
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IMPACT OF MMRV MASS VACCINATION WITH OR WITHOUT A 
CATCH UP PROGRAM ON THE INCIDENCE OF VARICELLA 
COMPLICATIONS IN FRANCE
Ouwens M1, Littlewood K1, Sauboin C2, Tehard B3, Alain S4, Denis F5, Boelle PY6
1Mapi Values, Houten, The Netherlands; 2GlaxoSmithKline Biologicals, Rixensart, Belgium; 
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OBJECTIVES: Varicella complications place a large burden on health care resources, 
however, varicella is preventable by mass vaccination with MMRV. The impact on 
complications of three MMRV programs were explored. METHODS: An age-struc-
tured dynamic model compared natural and breakthrough varicella following mass 
vaccination, to current cases. Age-speciﬁ c complication rates (neurologic, cutaneous, 
pulmonary, other) were applied per case. MMRV replaced 80% of MMR over 1 year 
(basecase) compared to 100% of MMR with a catch-up in 11–13 year-olds (‘catch 
up’). In an ‘optimal’ scenario, MMR coverage increased from 90% to 95% (1st dose) 
and 60% to 90% (2nd dose), MMRV replaced 100% MMR within 1 year with a 
catch-up in 10 year-olds. RESULTS: MMRV decreased varicella incidence and caused 
an age shift, however, many post-vaccination cases were breakthrough cases, believed 
to be milder and require less resource use. Prior to MMRV: highest varicella incidence 
(per million-person-years of total population) was among 1–4 year-olds (7,482 cases), 
with 355 complications (age-speciﬁ c complication rate: 4.75%). Basecase: highest 
incidence among 10–14 year-olds (907 natural, 633 breakthrough), with 54 complica-
tions (age-speciﬁ c rate: 3.53%); 85% lower versus 1–4 year-olds. ‘Catch-up’: highest 
incidence among 15–24 year-olds (161 natural, 398 breakthrough), with 49 complica-
tions (age-speciﬁ c rate: 8.82%); 86% lower versus 1–4 year-olds. ‘Optimal’: highest 
incidence among 15–24 year-olds (22 natural, 80 breakthrough), with 9 complica-
tions; 97.5% lower versus 1–4 year-olds. Assuming breakthrough cases have 10% of 
complications of natural cases, the incidence in the basecase, catch-up and optimal 
scenarios becomes: 34, 18 and 3 complications respectively. Despite greater risks of 
complications in older age groups, the reduction in varicella cases signiﬁ cantly reduced 
the incidence of complications. The ICER remained below c16,000 (direct costs). 
CONCLUSIONS: Mass varicella vaccination is predicted to signiﬁ cantly reduce vari-
cella and complication cases. As many vaccine era cases will be breakthrough; burden 
to patients and health care systems may be reduced further.
PIN5
HOW LONGITUDINAL PATIENT RECORDS CAN HELP PUBLIC HEALTH 
AUTHORITIES IN THE MANAGEMENT OF RAPIDLY GROWING 
EPIDEMICS? THE EXPERIENCE OF FLU A/H1N1 IN FRANCE
Toussi M, Pertus D, Antonio M, Robain M
CSD, Boulogne, Billancourt, France
OBJECTIVES: In the context of an epidemic, public health authorities need to have 
real time information of the disease propagation to make appropriate and timely 
decisions. We present our experience in using centralized electronic patient records in 
the early detection and follow-up of Flu A/H1N1 epidemic in France. METHODS: 
We used Longitudinal Patient Data (LPD), which is a dynamic centralized database 
of more than 1.3 million anonymous patient records uploaded regularly by a network 
of 1300 representative general practitioners and pediatricians in France. The trends 
of seasonal inﬂ uenza, Flu A/H1N1 and ﬂ u-like syndrome diagnoses are traced and 
compared with the reports published by Sentinel Network, a group of trained physi-
cians set up by public authorities. RESULTS: The trends of seasonal inﬂ uenza, Flu A/
H1N1, and ﬂ u-like syndrome obtained from LPD database show a very close similarity 
with those published by Sentinel Network (Pearson’s correlation coefﬁ cient = 0.97). 
The seasonal pattern of the incidence of inﬂ uenza and ﬂ u-like syndrome were less 
similar between 2009 and 2008 (Pearson’s correlation coefﬁ cient = 0.60), which can 
be explained by an over declaration of all kinds of ﬂ u by the doctors during the second 
half of 2009. There was also a close similarity between seasonal Flu, approved Flu A/
H1N1, and ﬂ u-like syndrome trends with a peak incidence in late November 2009. 
CONCLUSIONS: The LPD data matched very closely the results published by the 
